TY - JOUR
T1 - Rate control versus rhythm control for atrial fibrillation after cardiac surgery
AU - Gillinov, A. Marc
AU - Bagiella, Emilia
AU - Moskowitz, Alan J.
AU - Raiten, Jesse M.
AU - Groh, Mark A.
AU - Bowdish, Michael E.
AU - Ailawadi, Gorav
AU - Kirkwood, Katherine A.
AU - Perrault, Louis P.
AU - Parides, Michael K.
AU - Smith, Robert L.
AU - Kern, John A.
AU - Dussault, Gladys
AU - Hackmann, Amy E.
AU - Jeffries, Neal O.
AU - Miller, Marissa A.
AU - Taddei-Peters, Wendy C.
AU - Rose, Eric A.
AU - Weisel, Richard D.
AU - Williams, Deborah L.
AU - Mangusan, Ralph F.
AU - Argenziano, Michael
AU - Moquete, Ellen G.
AU - O'Sullivan, Karen L.
AU - Pellerin, Michel
AU - Shah, Kinjal J.
AU - Gammie, James S.
AU - Mayer, Mary Lou
AU - Voisine, Pierre
AU - Gelijns, Annetine C.
AU - O'Gara, Patrick T.
AU - Mack, Michael J.
N1 - Funding Information:
Funded by the National Institutes of Health and the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT02132767. Supported by a cooperative agreement (U01 HL088942) funded by the National Heart, Lung, and Blood Institute and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health, Bethesda, MD, and the Canadian Institutes of Health Research.Dr. Gillinov reports receiving consulting fees from AtriCure, Medtronic, Edwards Lifesciences, St. Jude Medical, Abbott, On-X, ClearFlow, and Tendyne, lecture fees from AtriCure and Medtronic, and grant support from St. Jude Medical, having an equity interest in ClearFlow, and holding a patent related to a mitralvalve repair device (US 8439969 B2); Dr. Ailawadi, receiving consulting fees from Abbott Vascular, AtriCure, Edwards Lifesciences, St. Jude Medical, and Mitralign; Dr. Kern, receiving fees for serving on an advisory board from Sorin; Dr. Gammie, receiving consulting fees from Edwards Lifesciences, being the founder of Harpoon Medical and Correx, and holding patents related to a surgical method and apparatus for treating atrial fibrillation (US 7740627 B2), an apparatus and method for forming a hole in a wall of a hollow organ (US 7799041 B2), and a transapical mitral-valve repair device (US 8852213 B2, licensed to Harpoon Medical), and a pending patent related to a transapical mitral-valve repair method (US 20150032127 A1); and Dr. Gelijns, having an equity interest in MERS International. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
Copyright © 2016 Massachusetts Medical Society.
PY - 2016/5/19
Y1 - 2016/5/19
N2 - BACKGROUND: Atrial fibrillation after cardiac surgery is associated with increased rates of death, complications, and hospitalizations. In patients with postoperative atrial fibrillation who are in stable condition, the best initial treatment strategy - heart-rate control or rhythm control - remains controversial. METHODS: Patients with new-onset postoperative atrial fibrillation were randomly assigned to undergo either rate control or rhythm control. The primary end point was the total number of days of hospitalization within 60 days after randomization, as assessed by the Wilcoxon ranksum test. RESULTS: Postoperative atrial fibrillation occurred in 695 of the 2109 patients (33.0%) who were enrolled preoperatively; of these patients, 523 underwent randomization. The total numbers of hospital days in the rate-control group and the rhythm-control group were similar (median, 5.1 days and 5.0 days, respectively; P = 0.76). There were no significant between-group differences in the rates of death (P = 0.64) or overall serious adverse events (24.8 per 100 patient-months in the rate-control group and 26.4 per 100 patient-months in the rhythm-control group, P = 0.61), including thromboembolic and bleeding events. About 25% of the patients in each group deviated from the assigned therapy, mainly because of drug ineffectiveness (in the rate-control group) or amiodarone side effects or adverse drug reactions (in the rhythm-control group). At 60 days, 93.8% of the patients in the rate-control group and 97.9% of those in the rhythm-control group had had a stable heart rhythm without atrial fibrillation for the previous 30 days (P = 0.02), and 84.2% and 86.9%, respectively, had been free from atrial fibrillation from discharge to 60 days (P = 0.41). CONCLUSIONS: Strategies for rate control and rhythm control to treat postoperative atrial fibrillation were associated with equal numbers of days of hospitalization, similar complication rates, and similarly low rates of persistent atrial fibrillation 60 days after onset. Neither treatment strategy showed a net clinical advantage over the other.
AB - BACKGROUND: Atrial fibrillation after cardiac surgery is associated with increased rates of death, complications, and hospitalizations. In patients with postoperative atrial fibrillation who are in stable condition, the best initial treatment strategy - heart-rate control or rhythm control - remains controversial. METHODS: Patients with new-onset postoperative atrial fibrillation were randomly assigned to undergo either rate control or rhythm control. The primary end point was the total number of days of hospitalization within 60 days after randomization, as assessed by the Wilcoxon ranksum test. RESULTS: Postoperative atrial fibrillation occurred in 695 of the 2109 patients (33.0%) who were enrolled preoperatively; of these patients, 523 underwent randomization. The total numbers of hospital days in the rate-control group and the rhythm-control group were similar (median, 5.1 days and 5.0 days, respectively; P = 0.76). There were no significant between-group differences in the rates of death (P = 0.64) or overall serious adverse events (24.8 per 100 patient-months in the rate-control group and 26.4 per 100 patient-months in the rhythm-control group, P = 0.61), including thromboembolic and bleeding events. About 25% of the patients in each group deviated from the assigned therapy, mainly because of drug ineffectiveness (in the rate-control group) or amiodarone side effects or adverse drug reactions (in the rhythm-control group). At 60 days, 93.8% of the patients in the rate-control group and 97.9% of those in the rhythm-control group had had a stable heart rhythm without atrial fibrillation for the previous 30 days (P = 0.02), and 84.2% and 86.9%, respectively, had been free from atrial fibrillation from discharge to 60 days (P = 0.41). CONCLUSIONS: Strategies for rate control and rhythm control to treat postoperative atrial fibrillation were associated with equal numbers of days of hospitalization, similar complication rates, and similarly low rates of persistent atrial fibrillation 60 days after onset. Neither treatment strategy showed a net clinical advantage over the other.
UR - http://www.scopus.com/inward/record.url?scp=84969715726&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1602002
DO - 10.1056/NEJMoa1602002
M3 - Article
C2 - 27043047
AN - SCOPUS:84969715726
SN - 0028-4793
VL - 374
SP - 1911
EP - 1921
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 20
ER -